Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 50

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 50
---
 period of
    time. To date, we have not submitted an application for orphan drug designation;

    ●
    On December 23,
    2023, we entered into the Benuvia License Agreement. We are dependent on the Benuvia License Agreement, and the termination
    of the Benuvia License Agreement could have an adverse effect on our business;

    ●
    If Benuvia does
    not properly maintain or enforce the intellectual property underlying the Benuvia License Agreement, our competitive position
    and business prospects could be harmed. Benuvia may also seek to terminate our license;

28 

    ●
    If the
    market opportunities for CC8464, CT2000, CT3000 or our future compounds are smaller than we believe they are, our revenues
    may be adversely impacted, and our business may suffer;

    ●
    Government price
    controls or other changes in pricing regulation could restrict the amount that we are able to charge for CC8464, CT2000 and
    CT3000, if approved, or any of our other future compounds that may be approved in the future, which would adversely affect
    our revenue and results of operations;

    ●
    If we are unable
    to obtain and maintain adequate U.S. and foreign patent protection for our compounds, including CC8464, CT2000 and CT3000,
    or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize
    products and technologies similar or identical to ours, and our ability to successfully commercialize CC8464, CT2000, CT3000
    and any of our other current or future compounds may be adversely affected; 

    ●
    We could issue “blank
    check” preferred stock without stockholder approval with the effect of diluting then current stockholder interests and
    impairing their voting rights; and provisions in our charter documents could discourage a takeover that stockholders may consider
    favorable;

    ●
    Our articles of
    incorporation (which, as may be amended and/or restated, we refer to as our “articles of incorporation”) designate
    the Second Judicial District Court, in and for the State of Nevada, located in Washoe County, Nevada, as the exclusive forum
    for certain types of actions and proceedings that may be initiated by our stockholders, which could limit stockholders’
    ability to obtain a favorable judicial forum for disputes with us